Proactive Investors - Run By Investors For Investors

NetScientific portfolio company Vortex presents study to combine technology with impedance spectroscopy

The healthcare IP commercialisation group said the study introduced the coupling of Vortex’s technology with an impedance chip for counting and sizing cancer cells
Cells and test tubes
The study will be presented at the NanoBiotech Montreux 2018 conference in Switzerland

NetScientific PLC (LON:NSCI) said its portfolio company, Vortex BioSciences, has presented a study demonstrating how its technology can combine with impedance spectroscopy to improve the analysis of circulating tumour cells (CTCs).

The healthcare IP commercialisation group said the study, presented at the NanoBiotech Montreux 2018 conference in Switzerland, introduced the coupling of Vortex’s technology with an impedance chip for counting and sizing cancer cells isolated from blood samples.

READ: NetScientific portfolio company Vortex enters manufacturing partnership with STRATEC

The researchers believed the results of the study provided feasibility for label-free, reliable, fully-integrated cell enumeration, whilst keeping the cells collected intact for downstream transcriptomic, genomic or proteomic analysis.

Impedance spectroscopy involves applying a wave frequency to a system or surface and measuring the changes and is often used on various types of biological tissue.

Francois Martelet, chief executive of NetScientific and chairman of Vortex, said Vortex’s technology was “ready to be adopted by large pharmaceutical players” following the creation of an automated and reliable process and the signing of a manufacturing agreement with German firm STRATEC for its VTX-1 liquid biopsy platform in November.

View full NSCI profile View Profile

Netscientific PLC Timeline

Related Articles

1537236236_main-better-use.jpg
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
1550762209_shutterstock_291998651.jpg
February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections
Hep C
November 22 2018
The company made positive operational progress in the year to June 30.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use